Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world.

ABSTRACT:

Background

Since the FLOT4 gastric cancer (GC) trial, the use of adjuvant chemotherapy has been perceived as limited and its added value questioned. We wanted to objectify this perception and reassess the value of adjuvant chemotherapy in a real-world setting.

Methods

In our retrospective cohort study we analyzed real-world data from 147 patients with GC or cancer of the gastroesophageal junction (AEG) who received perioperative FLOT. Data originated from clinical care at the university hospital, local hospitals and medical practices. Clinicopathologic data, survival outcomes, and targetable biomarkers were analyzed.

Results

Median overall survival (OS) and tumor specific survival (TSS) were 19.4 ± 2.9 and 19.9 ± 3.1 months, respectively. 84.4% completed all cycles of

SUBMITTER: Heckl SM 

PROVIDER: S-EPMC12378129 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature